Pharmaxis' Bronchitol to get NHS listing in UK

Pharmaxis (ASX:PXS) has received the final approval required to have its Bronchitol cystic fibrosis treatment cleared for reimbursement by the UK National Health Service.

The UK's National Institute for Health and Clinical Excellence (NICE) has issued a positive recommendation in its final appraisal of the product, paving the way for the NHS listing.

Bronchitol is the only cystic fibrosis product to date to receive a positive recommendation from NICE.

Pharmaxis launched Bronchitol in the UK as well as Germany in June, after receiving European marketing approval for the product in April.

In the UK, Pharmaxis is cleared to sell Bronchitol as a treatment for adult cystic fibrosis patients as an add-on therapy to the standard of care.

Bronchitol is a proprietary formulation of mannitol administered as a dry powder through an inhaler. It is also approved in Australia for use in cystic fibrosis, and is listed on the Pharmaceutical Benefits Scheme.

Besides cystic fibrosis, Pharmaxis is also developing Bronchitol as a treatment for bronchiectasis and chronic bronchitis.

Pharmaxis (ASX:PXS) shares were trading 4.8% higher at $1.310 as of around 2pm on Friday.